Overcoming the Clinical–MR Imaging Paradox of Multiple Sclerosis: MR Imaging Data Assessed with a Random Forest Approach

References

1. 1.↵
   1. Bakshi R,
   2. Thompson AJ,
   3. Rocca MA,
   4. et al

   . MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 2008;7:615–25

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Barkhof F,
   2. Calabresi PA,
   3. Miller DH,
   4. et al

   . Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009;5:256–66

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Kurtzke JF

   . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–52

   Abstract/FREE Full Text
4. 4.↵
   1. Lassmann H

   . The pathologic substrate of magnetic resonance alterations in multiple sclerosis. Neuroimaging Clin N Am 2008;18:563–76, ix

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Pagani E,
   2. Filippi M,
   3. Rocca MA,
   4. et al

   . A method for obtaining tract-specific diffusion tensor MRI measurements in the presence of disease: application to patients with clinically isolated syndromes suggestive of multiple sclerosis. Neuroimage 2005;26:258–65

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Mesaros S,
   2. Rocca MA,
   3. Riccitelli G,
   4. et al

   . Corpus callosum damage and cognitive dysfunction in benign MS. Hum Brain Mapp 2009;30:2656–66

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Cutter GR,
   2. Baier ML,
   3. Rudick RA,
   4. et al

   . Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122(pt 5):871–82

   Abstract/FREE Full Text
8. 8.↵
   1. Rovaris M,
   2. Agosta F,
   3. Pagani E,
   4. et al

   . Diffusion tensor MR imaging. Neuroimaging Clin N Am 2009;19:37–43

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Breiman L

   . Random forests. Mach Learn 2001;45:5–32

   CrossRefWeb of Science
10. 10.↵
    1. Polman CH,
    2. Reingold SC,
    3. Edan G,
    4. et al

    . Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 2005;58:840–46

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Lublin FD,
    2. Reingold SC

    . Defining the clinical course of multiple sclerosis: results of an international survey—National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907–11

    Abstract/FREE Full Text
12. 12.↵
    1. Hawkins SA,
    2. McDonnell GV

    . Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999;67:148–52

    Abstract/FREE Full Text
13. 13.↵
    1. Pittock SJ,
    2. McClelland RL,
    3. Mayr WT,
    4. et al

    . Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol 2004;56:303–06

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Montalban X,
    2. Sastre-Garriga J,
    3. Filippi M,
    4. et al

    . Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. Mult Scler 2009;15:1459–65

    Abstract/FREE Full Text
15. 15.↵
    1. Smith SM,
    2. De Stefano N,
    3. Jenkinson M,
    4. et al

    . Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001;25:466–75

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Basser PJ,
    2. Mattiello J,
    3. LeBihan D

    . MR diffusion tensor spectroscopy and imaging. Biophys J 1994;66:259–67

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Basser PJ,
    2. Pierpaoli C

    . Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B 1996;111:209–19

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Ceccarelli A,
    2. Rocca MA,
    3. Falini A,
    4. et al

    . Normal-appearing white and grey matter damage in MS: a volumetric and diffusion tensor MRI study at 3.0 Tesla. J Neurol 2007;254:513–18

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Rocca MA,
    2. Pagani E,
    3. Absinta M,
    4. et al

    . Altered functional and structural connectivities in patients with MS: a 3-T study. Neurology 2007;69:2136–45

    Abstract/FREE Full Text
20. 20.↵
    1. Rocca MA,
    2. Valsasina P,
    3. Ceccarelli A,
    4. et al

    . Structural and functional MRI correlates of Stroop control in benign MS. Hum Brain Mapp 2009;30:276–90

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Losseff NA,
    2. Kingsley DP,
    3. McDonald WI,
    4. et al

    . Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis. Mult Scler 1996;1:218–22

    PubMed
22. 22.↵
    1. Filippi M,
    2. Rocca MA

    . Magnetization transfer magnetic resonance imaging of the brain, spinal cord, and optic nerve. Neurotherapeutics 2007;4:401–13

    CrossRefPubMed
23. 23.↵
    1. Efron B,
    2. Tibshirani R

    . Improvements on cross-validation: the .632+ bootstrap method. J Am Stat Ass 1997;92:548–60

    CrossRefWeb of Science
24. 24.↵
    1. Strobl C,
    2. Boulesteix AL,
    3. Zeileis A,
    4. et al

    . Bias in random forest variable importance measures: illustrations, sources and a solution. BMC Bioinformatics 2007;8:25

    CrossRefPubMed
25. 25.↵
    1. Strobl C,
    2. Boulesteix AL,
    3. Kneib T,
    4. et al

    . Conditional variable importance for random forests. BMC Bioinformatics 2008;9:307

    CrossRefPubMed
26. 26.↵
    1. Filippi M,
    2. Rocca MA

    . Conventional MRI in multiple sclerosis. J Neuroimaging 2007;17(suppl 1):3S–9S

    CrossRefPubMed